

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
16 June 2022 (16.06.2022)



(10) International Publication Number
WO 2022/125572 A1

(51) International Patent Classification:

A61K 31/135 (2006.01) A61P 25/00 (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:

PCT/US2021/062244

(22) International Filing Date:

07 December 2021 (07.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/122,469 07 December 2020 (07.12.2020) US

(71) Applicant: **TONIX PHARMACEUTICALS HOLDING CORP.** [US/US]; 26 Main Street, Suite 101, Chatham, New Jersey 07928 (US).

(72) Inventors: **LEDERMAN, Seth**; 124 Misham Point Road, South Dartmouth, Massachusetts 02748 (US). **SULLIVAN, Gregory M.**; 230 Mapes Rd., Barryville, New York 12719 (US).

(74) Agent: **HALEY, James F., Jr.** et al.; **HALEY GUILIANO LLP**, 75 Broad Street, Suite 1000, New York, New York 10004 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CYCLOBENZAPRINE TREATMENT FOR FIBROMYALGIA



(57) Abstract: Methods for treating fibromyalgia and one or more of its associated symptoms of pain, sleep disturbance and/or fatigue comprising administering to a subject in need thereof, 5.6 mg cyclobenzaprine HCl per day in one or more dosage units by transmucosal administration, the cyclobenzaprine HCl being in a form of a eutectic, and the one or more dosage units further comprising a basifying agent.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*